Drugs / ANOC-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07145450 | Jul 2025 → Apr 2030 expected | pancreatic ductal adenocarcinoma | Anocca AB | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANOC-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07145450 ↗ |
| Modality | Cell therapy | “engineered autologous T cells” NCT07145450 ↗ |
| Route | Intravenous | “administered by a single IV infusion” NCT07145450 ↗ |
| Target | KRAS | “TCR-T cells targeting KRAS G12D mutation” NCT07145450 ↗ |